Lecanemab Use at MCI Stage Might Have Larger Impact on Delaying AD Progression: Eisai

Eisai says that its Alzheimer’s disease (AD) modifying drug lecanemab, marketed under the brand name Leqembi in the US, might help slow symptom progression and extend the duration of early-stage AD, possibly improving a patient’s quality of life. The company...read more